...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The European Journal of Neuroscience >Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.
【24h】

Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome.

机译：白细胞介素6和IL6 / IL6R嵌合体在亨廷顿综合征大鼠喹啉酸大鼠模型中的神经保护作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ciliary neurotrophic factor prevents behavioural deficits and striatal degeneration in rat and primate models of Huntington's disease. Interleukin-6, another member of the cytokine family, and the chimeric molecule (IL6/IL6R) in which interleukin-6 and its soluble receptor are fused, have been shown to exert trophic action on various neuronal populations in the central nervous system. Therefore, we investigated the neuroprotective effect of these two molecules in the quinolinic acid model of Huntington's disease. LacZ-, interleukin-6- and IL6/IL6R-expressing lentiviral vectors were stereotaxically injected into the striatum of Wistar rats. Three weeks later the animals were lesioned through the intrastriatal injection of 180 nmol of quinolinic acid. The extent of the striatal damage was significantly diminished in the rats that had been treated with interleukin-6 or IL6/IL6R. The neuroprotective effect was, however, more pronounced with the IL6/IL6R chimera than with interleukin-6 as indicated by the volume of the lesions (38.6 +/- 10% in the IL6/IL6R group, 63.3 +/- 3.6% in the IL-6 group and 84.3 +/-2.9% in the control group). Quantitative analysis of striatal interneurons further demonstrated that the IL6/IL6R chimera is more neuroprotective than IL-6 on ChAT- and NADPH-d-immunoreactive neurons. These results suggest that the IL6/IL6R chimera is a potential treatment for Huntington's disease.
机译：睫状神经营养因子可预防亨廷顿氏病大鼠和灵长类动物模型中的行为缺陷和纹状体变性。细胞因子家族的另一成员白细胞介素-6，以及将白细胞介素6及其可溶性受体融合的嵌合分子（IL6 / IL6R），已被证明对中枢神经系统的各种神经元群体具有营养作用。因此，我们研究了这两种分子在亨廷顿氏病喹啉酸模型中的神经保护作用。将表达LacZ-，白介素-6-和IL6 / IL6R的慢病毒载体立体定位注射到Wistar大鼠的纹状体中。三周后，通过纹状体内注射180nmol喹啉酸使动物受损伤。在用白介素6或IL6 / IL6R治疗的大鼠中，纹状体损伤的程度明显降低。但是，IL6 / IL6R嵌合体的神经保护作用比白介素6更为明显，如病变体积所示（IL6 / IL6R组为38.6 +/- 10％，IL6 / IL6R组为63.3 +/- 3.6％）。 IL-6组，对照组为84.3 +/- 2.9％）。纹状体中间神经元的定量分析进一步表明，在ChAT-和NADPH-d免疫反应性神经元上，IL6 / IL6R嵌合体比IL-6更具神经保护作用。这些结果表明IL6 / IL6R嵌合体是亨廷顿氏病的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号